ARS Pharmaceuticals Inc. (NASDAQ:SPRY)

There are currently no videos for this stock.
To request coverage of this stock, please click the green request video box on the right.
Bands Volume 200 SMA 50 SMA 20 SMA Videos Alerts Articles Events
SPRY Weekly Chart

Old Forum Content for SPRY

Make a Forum Post
Become a member to view recent forum posts. Already a member? Sign in here.
Loading...
  • Onthemark: $MREO, $ARDX and $SPRY moving nicely today.
  • Onthemark: Took some partial profits on $SPRY, which is headed higher as it trends up the 8d, Like $MREO at $3 and holding some $HRTX.
  • Onthemark: Up over 100 percent since Nov on $SPRY, and the best is yet to come on this one. Long.
  • Onthemark: Also holding $ARDX and $SPRY, which are taking a little break today.
  • Onthemark: @woodman $MDXH I did get some more $SPRY at 5.72 today. Resistance is at 6 at the 200d, but it keeps chugging along to fill the gap up to 7. Started buying back in Sept at 3. Wedbush gives it an Outperform and a PT of 13.
  • Onthemark: Riding $SPRY as it fills the gap, now over the 200d. Mentioned this last month when it was around $5.20 now over $6. FDA approval expected later this year, which could push this for a double.
  • Onthemark: @champ $GTLS $JPM #News-flow #might Been long $GTLS, also liking other longs $SPRY, $TLRY, $HTZ, and $OLLI
  • champ: @Onthemark $GTLS $JPM $SPRY $TLRY $HTZ $OLLI #News-flow #might....Real nice and I'm also holding $OLLI and it is my #largest-position.....and I will check out those other 3....Good Luck!
  • Onthemark: @woodman $ARDX Yes, thank you for letting all of us know about this company when it was so much lower. Those that got involved should have done quite well so far, and look forward to higher prices. If I can return the favor, I would point out $SPRY as a good 2024 story, since it did receive FDA committee approval for its nasal spray in 2023 only to be asked for addition results which will be provided in the first half of 2024. The stock did drop on the disappointment, but has been in a basing pattern, with a slight upward bias.
  • Onthemark: $SPRY Filling up the gap as it rides up the 8dma. Approval of the nasal spray expected next year.
  • oldmaratom: $SPRY#Wedbush analyst Andreas Arygrides maintains outperform with $13 pt.
  • Onthemark: $SPRY, $LABU, $ETHE, $COIN and $GBTC Long and added to each
  • Onthemark: @champ #TGIFriday #Great-Weekend Have a great weekend too. As a spec take a look at $SPRY. It's filling the gap now.
  • Zimzala: $SPRY On the move. Only have a tracking position.
  • Onthemark: @Zimzala $SPRY Took some profits at $4.05. Still holding a few, but this is a play on next year's FDA approval.
  • Onthemark: $SPRY Nice recovery going on in this spec biotech. IMO, the nasal spray will eventually be approved.
  • MongosPawn: $SPRY Added small.
  • vitoB: @MongosPawn $SPRY pin action from $PNT buyout by $LLY
  • MongosPawn: $SPRY Added small.
  • Onthemark: @MongosPawn $SPRY Adding as well. Insider bought 2.7 million shares after learning about the delay. An 8 million dollar purchase last week.
  • woodman: @Onthemark @MongosPawn $SPRY - great job with this one. I wish I jumped on it.
  • Onthemark: $SPRY I added at yesterday's close since the drug will eventually be approved. At $3.58 its up .65 today, (22 percent). Looking to get up to near $5 in the short term and wait for the approval.
  • Onthemark: $SPRY - Here's what happened: The FDA surprised ARS Pharmaceuticals—if the tone of the company’s press release is any indication—by issuing a Complete Response Letter for neffy, an epinephrine nasal spray, in type 1 allergic reacti ...
  • woodman: @Onthemark $SPRY - Ugh!
  • joelsg1: @Onthemark $SPRY I smelled a rat with the timing of the FDA's cold medicine statement, as posted.
  • Onthemark: @joelsg1 $SPRY IMO: I think that the argument submitted by the EpiPen manufactures, Meridian Medical Technologies, and marketed by Mylan, which has dominated the market had a great deal to do with the failure to approve at this time. By the way. do you know who owns Meridian? It just happens to be a subsidiary of PFIZER. So now you know the rest of the story....
  • Onthemark: @joelsg1 $SPRY Your sense of smell was right on, but I believe for a different reason
  • woodman: @joelsg1 $SPRY - I had no position in SPRY, but the one thing that always lingers in my mind with any biotech I own is FDA conflicts of interest. Who is buttering the bread of or applying massive pressure upon the folks over there? In the case of SPR ...
  • woodman: @Onthemark $SPRY - Pfizer sold its subsidiary Meridian to Alteris in 2021.But who knows how the bread-buttering works over at FDA.
  • Onthemark: $SPY broke below 442. Exited most positions taking profits and small losses. Holding $GOOGL, $LLY, $WFC, $DBRG, some energy $WFRD, $OXY and a couple bio specs, $ARDX and $SPRY.
  • Henry: $SPRY no word on the PDUFA scheduled for today, stock is down 3.6% on 150% of normal volume.
  • Onthemark: @Henry $SPRY Yes, disappointing, but patiently waiting for some information.
  • Henry: @Onthemark $SPRY I looked on the FDA site and I can't find any committee info for the drug.
  • Onthemark: $SPRY - just a note that the company is expecting FDA approval tomorrow of its epinephrine nasal spray for patients with type I allergic reactions. Of course there is opposition by the makers of the Epipen, but the nasal spray would be more widely used if approved.
  • joelsg1: @Onthemark $SPRY What about FDA criticism of phenylephrine in cold medications last week, similar compounds.
  • Henry: @joelsg1 $SPRY chemically very similar, clinically very different. The goal of therapy is different too.
  • Onthemark: @joelsg1 $SPRY The FDA’s Pulmonary-Allergy Drugs Advisory Committee voting 16–6, found that ARS’ data showed a favorable risk-benefit profile of using neffy in adults. The split was 17–5 for allowing the nasal spray in children aged 18 years or below. The meeting was held on May 11, 2023. The Agency informed ARS that it requires additional time to complete its review; however, no additional pre-marketing studies have been requested and ARS has addressed all other information requests from the Agency to date. The additional time is needed for labeling and post-marketing commitment discussions regarding neffy, and ARS has submitted proposals for post-marketing commitments based on input from the PADAC meeting in May.
  • Onthemark: @Onthemark $SPRY The main concern is that the nasal spray takes a bit more time to enter the system than an injection, but the FDA panel voted to approve based upon the favorable risk-benefit the spray provided, and that more allergic patients would use the spray over an injection.
  • Onthemark: $SPRY a biotech up on a down day. $SPRY develops treatments for severe allergic reactions. It is developing neffy, a needle-free epinephrine nasal spray for patients with type I allergic reactions, including anaphylaxis. FDA approval decision anticipated on Sept. 19th.
  • Onthemark: $SPRY Breakout from squeeze pattern. Big investments reported in the stock this week. Anticipated FDA approval on Sept 19.
  • Onthemark: $SPRY for those bio players, this one has an FDA decision coming on 9/19. The chart is in a very tight squeeze. In early now to catch the pop if approved.
  • Onthemark: $SPRY May be nearing resistance, but seems to want to go higher.
  • Onthemark: $SPRY great move, long. IMO at resistance now, waiting for pb to add.
  • sgiseller: $BLUE $SPRY $ ARRY all on the move
Visit the Trading Forum to join in the discussion.
Stock Price $8.35
Change 3.21%
Volume 520,296

ARS Pharmaceuticals Inc is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The company is developing neffy, an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications, and insect bites that could lead to life-threatening anaphylaxis.

Request Video of SPRY
Already a member? Sign in here.
Past Month

Leading Peers

Past Month

Lagging Peers

Dan Fitzpatrick

Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:

  • Nightly video Strategy Sessions with a game plan for tomorrow
  • Got a stock you want Dan to look at? Just ask.
  • Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
  • Access to over 90,400 stock analysis videos
  • Access an ever expanding library (90,400) of educational videos that will save you time and make you money

Join a team of friends and traders that have one thing in common; a burning desire to succeed.

Become a Member Today!

Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...

Satisfaction Guaranteed!

Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!